Subventions financées

Major depression is common, highly prevalent, potentially lethal, affecting 10% of individuals with significant increase between 2015-2020, and 2-3-fold higher incidence in women compared to men.

We identified changes in the gene called IRF2BPL (Interferon Regulatory Factor 2 Binding Protein Like) as the cause of a severe brain disorder in children called NEDAMSS (Neurodevelopmental disorder with abnormal movements, loss of speech and seizures).

Mutations in the metabolic enzymes are commonly observed in brain cancers.

A common feature in almost all ALS cases is the build up of a protein called TDP-43 in the brain and spinal cord.

We are studying a type of brain tumour called glioblastoma (GBM), which is often fatal despite current treatments.

Led by Dr. Elie Haddad from CHU Sainte-Justine in collaboration with Immugenia, this project includes an inter-provincial research collaboration

Kendra Loedige, a Master’s student at the University of Western Ontario, aims to understand how genetic variations in CADM2 contributes to mental illness and substance use disorders by identifying specific genes that could serve as therapeutic targets.

The immune system is responsible for protecting the body against diseases, but it can also play a role in tumor formation.

Melanoma brain metastases (MBMs) are a serious issue affecting up to half of all patients with stage IV melanoma, typically leading to a poor outlook.

Led by Dr. Jocelyn Faubert from the Université de Montréal in collaboration with Neurotracker Athletics Inc., this project includes an inter-provincial research collaboration with Prof. Brian Christie and Prof. Jodie Gawryluk from the University of Victoria.